Hemcheck has concluded the prepatory phase of the Bridgehead Europe program by selecting two focus markets and two local partners to support Hemcheck in the internationalization process. For the Netherlands, Hemcheck has decided to partner with Medscaler and for France, Medicen was chosen as the local partner. The actual work to accelerate the commercial efforts in the respective countries within the program will begin in September.

– We really look forward to working with Medscaler and Medicen and believe they can support us and help accelerate our commercialization efforts in the local markets. Both have good and relevant expert networks as well as experience and knowledge about the local healthcare systems, which will be very helpful for Hemcheck, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

For more info about Medscaler and Medicen, please visit their websites

About Medscaler

www.medscaler.com

About Medicen

https://medicen.org/en/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.